Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candida... Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. Mostrar más
Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...
Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1...
Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and...
LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | -49.43 | -73.5237245277 | 67.23 | 72.37 | 16.86 | 496051 | 67.20221465 | CS |
| 4 | -45.22 | -71.7549984132 | 63.02 | 72.37 | 16.86 | 447159 | 60.53730239 | CS |
| 12 | -39.41 | -68.886558294 | 57.21 | 72.37 | 16.86 | 389895 | 60.47959718 | CS |
| 26 | -31.18 | -63.658636178 | 48.98 | 72.37 | 16.86 | 375328 | 54.17901278 | CS |
| 52 | -10.63 | -37.3900809005 | 28.43 | 73 | 16.86 | 379021 | 54.43201089 | CS |
| 156 | -35.84 | -66.8158090977 | 53.64 | 73 | 16.86 | 264082 | 47.76114129 | CS |
| 260 | -2.3 | -11.4427860697 | 20.1 | 88.8 | 16.86 | 219352 | 48.58312061 | CS |
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
